PT  - JOURNAL ARTICLE
AU  - Le Flahec, Glen
AU  - Briolais, Manon
AU  - Guibourg, Briac
AU  - Lemasson, Gilles
AU  - Grippari, Jean-Luc
AU  - Ledé, Francoise
AU  - Marcorelles, Pascale
AU  - Uguen, Arnaud
TI  - Testing for <em>BRAF</em> fusions in patients with advanced <em>BRAF</em>/<em>NRAS</em>/<em>KIT</em> wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy
AID  - 10.1136/jclinpath-2019-206026
DP  - 2020 Feb 01
TA  - Journal of Clinical Pathology
PG  - 116--119
VI  - 73
IP  - 2
4099  - http://jcp.bmj.com/content/73/2/116.short
4100  - http://jcp.bmj.com/content/73/2/116.full
SO  - J Clin Pathol2020 Feb 01; 73
AB  - Beyond targeted therapy for patients with BRAF-mutated melanomas and immunotherapy in patients lacking BRAF mutations, anti-MEK therapy has been proposed in patients with advanced melanomas harbouring BRAF fusions. BRAF fusions diagnosis in patients with advanced melanomas is the subject of the present study. Using BRAF fluorescent in situ hybridisation (FISH), we searched for BRAF fusions in 74 samples of 66 patients with advanced BRAF/NRAS/KIT wild-type melanomas. We identified 2/66 (3%) patients with BRAF fusions in a brain metastasis of one patient and in a lymph node metastasis and in a cutaneous metastasis for the second patient with 90%–95% of tumour nuclei containing isolated 3′-BRAF FISH signals. As a result, we conclude that BRAF FISH in patients with advanced BRAF/NRAS/KIT wild-type melanomas is a valuable and easy-to-perform test to diagnose BRAF fusions and to identify patients who could benefit of anti-MEK targeted therapy.